桥梁基因组学和药物流行病学,以扩大酒精使用障碍的治疗选择
Christopher T Rentsch1,2, Samantha G Malone3,4, Mingjian Shi3,4
1Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Alcohol, clinical & experimental research
|March 11, 2026
概括
这项研究开发了一种新的方法,以寻找用于治疗酒精使用障碍 (AUD) 的现有药物. 该方法成功地将巴克洛芬确定为一个有前途的候选人,在真实世界患者数据中显示了减少酒精消费.
科学领域:
- 遗传学和药理学 遗传学和药理学
- 公共卫生 公共卫生
- 数据科学数据科学数据科学
背景情况:
- 酒精使用障碍 (AUD) 是一个重要的公共卫生问题,有效的药物治疗方法有限.
- 药物再利用提供了一种具有成本效益的策略,以发现AUD的新疗法.
- 现有的AUD治疗方法的疗效有限,需要新的治疗方法.
研究的目的:
- 开发和验证一条管道,整合遗传和电子健康记录 (EHR) 数据,用于识别和评估AUD的药物重用候选人.
- 通过系统的药物重定向方法,发现用于酒精使用障碍的新型治疗剂.
主要方法:
- 从全基因组关联研究 (GWAS) 数据中确定了与酒精相关的基因和生成的生物网络.
- 将FDA批准的药物映射到向蛋白质,并根据安全性,相关性和数据可用性过候选药物.
- 使用EHR数据进行了药理流行病学分析,以评估巴克洛芬在减少酒精消费方面的实际有效性.
主要成果:
- 确定了327个与酒精有关的基因,并将其中的52个与FDA批准的195种药物联系起来.
- 选择了包括巴克洛芬在内的26种候选药物进行进一步评估.
- 药物流行病学分析表明,巴克洛芬的使用与实际患者群体的酒精消耗减少有关.
结论:
- 将基因组数据与现实世界的临床数据对齐的综合方法有效地确定了AUD的有希望的药物重定位候选人.
- 这种方法优先考虑随机试验中的药物,有可能推进酒精使用障碍的药物疗法.
- 这些发现支持巴克洛芬作为AUD的潜在治疗方法,需要进一步的临床研究.
更多相关视频
相关概念视频
01:29Pharmacogenomics: Identification of New Drug Targets
59
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
59
01:29Pharmacogenetics and Pharmacogenomics: Overview
109
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
109
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
81
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
81
01:27Pharmacogenetics of Drug Metabolism: Overview
84
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
84
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
61
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
55
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
55